Altamira Therapeutics Ltd. - $CYTO STOCK NEWS

Altamira Therapeutics announced the dissemination of positive results from its NASAR clinical trial for Bentrio nasal spray in treating seasonal allergic rhinitis (SAR). The trial's results, published in the Allergy journal's social media channels, showed significant efficacy and safety. The study, involving 100 patients in Australia, met its primary endpoint by significantly reducing the mean daily reflective Total Nasal Symptom Score (rTNSS) compared to saline (p = 0.013). Secondary endpoints also showed significant improvements in quality of life and global efficacy ratings (p < 0.001). Altamira expects Bentrio's sales to grow significantly with planned launches in new markets in 2024.

Altamira Therapeutics has filed a provisional patent application for OligoPhore nanoparticles with siRNA targeting p65 protein for the treatment of cancer and inflammation. The company aims to expand its IP portfolio focusing on RNA delivery technology, particularly for rheumatoid arthritis. The innovative approach utilizes siRNA to silence p65, a key protein involved in cancer and inflammatory diseases, including rheumatoid arthritis. Altamira's AM-411 program demonstrates promising results by delivering siRNA to inflamed tissues, offering potent treatment effects with reduced side effects and treatment resistance risks. Rheumatoid arthritis affects millions globally, with no cure currently available, making the development of effective treatments crucial.

Altamira Therapeutics announces positive results from the Bentrio trial in seasonal allergic rhinitis, with statistically significant improvements in nasal symptoms, quality of life, and reduced need for relief medication. The publication in a top peer-reviewed journal validates the effectiveness and safety of Bentrio, supporting plans for international expansion.

Altamira Therapeutics reports a successful year with a focus on RNA delivery technology, collaborations, and financial improvements. The company achieved an 85% reduction in net loss, eliminated financial debt, and increased shareholders' equity by CHF 14.8 million. Altamira is progressing with preclinical development of RNA delivery platforms for extrahepatic targets, showcasing promising results in cancer and osteoarthritis. Strategic collaborations with Heqet Therapeutics and Univercells Group aim to utilize Altamira's technology for heart tissue regeneration and mRNA vaccine delivery. The company is advancing development programs for KRAS-driven tumors and rheumatoid arthritis, with plans for IND filings in 2025. Altamira divested a stake in its subsidiary, Altamira Medica AG, for cash consideration and financial gain. The subsidiary's key asset, Bentrio nasal spray, demonstrated superior efficacy in allergic rhinitis treatment. Altamira is also focusing on partnering its inner ear therapeutics assets, particularly AM-125 for acute vestibular syndrome.

Altamira Therapeutics (CYTO) to host Full Year 2023 Financial Results and Business Update Call on April 10, 2024. Founders and executives to provide insights on company performance and future plans.

Altamira Therapeutics partners with Univercells Group to evaluate the use of its SemaPhore platform for delivering mRNA vaccines, aiming for safer and more accessible vaccination methods. The collaboration aims to test a proprietary mRNA vaccine using Altamira's nanoparticle technology. If successful, a commercial agreement for manufacturing nanoparticle-based mRNA vaccines may follow.

Altamira Therapeutics Ltd. (Nasdaq: CYTO) announced the publication of a peer-reviewed study showing enhanced cell transduction with adeno-associated virus (AAV) vectors using their peptide-based delivery technology. The study demonstrated increased potency, potentially reducing AAV immunogenicity and resistance to AAVs in certain cell types. The research evaluated 76 melittin derivatives, including p5RHH, which successfully enhanced cell transduction and transduced cell lines typically resistant to AAVs. In vivo studies in mice showed significant liver transduction enhancements with the addition of p5RHH to AAV capsids of several serotypes, up to four weeks after administration. Altamira's technology has the potential to lower the risk of immune responses and increase the safety of AAV-based vectors, opening new possibilities in gene therapy for cells and tissues typically resistant to transduction.

Altamira Therapeutics Ltd. (Nasdaq: CYTO) has filed a second provisional patent application with the USPTO for its polyKRASmut siRNA, showing a 65-91% knockdown of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines. The nanoparticles developed as AM-401 aim to provide broad coverage of different KRAS mutations in human cancer treatment. The data suggests that polyKRASmut siRNA has the potential to knock down other untested mutations, making it a promising treatment for severe types of cancer.

Altamira Therapeutics Ltd. (CYTO) to Present at 3rd Annual mRNA-Based Therapeutics Summit. Altamira's flagship programs, AM-401 and AM-411, target KRAS-driven cancer and rheumatoid arthritis, showcasing the technology's ability to enhance therapeutic efficacy. Covadonga Pañeda, Ph.D., Altamira's COO, will present on 'Delivery of therapeutic RNA in inflammation and cancer using peptide-based nanoparticles' at the conference.